Actualités et vidéos - KAMADA

KEDRION ANNOUNCES AN EIGHT-YEAR EXTENSION OF THE DISTRIBUTION AGREEMENT WITH KAMADA IN THE US FOR KEDRAB® PR Newswire CASTELVECCHIO PASCOLI, Italy, Dec. 7, 2023 Since 2018 Kedrion has had exclusive distribution rights in the US for KEDRAB ® , a Human Rabies Immune Globulin (HRIG) developed in partnership with Kamada Ltd. New agreement becomes effective in January 2024 and includes potential expansion of Kedrion's distribution of KEDRAB ® in additional territories beyond the US Rabies is a...

Thinking about buying stock in Coinbase Global, Pharvaris, Kamada, Minerva Surgical, or Brilliant Acquisition? PR Newswire NEW YORK, Dec. 6, 2023 NEW YORK , Dec. 6, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for COIN, PHVS, KMDA, UTRS, and BRLI. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link. COIN:...

Kedrion and Kamada Announce FDA Approval of KEDRAB® Label Update, Confirming Safety and Effectiveness in Children - Label Expansion Differentiates KEDRAB® as the First and Only Human Rabies Immune Globulin (HRIG) Available in the U.S. to be Clinically Studied in Children - KEDRAB Product Label Now Includes Patients of All Ages - New FDA Approval Based on Safety and Effectiveness of KEDRAB in the Pediatric Population Demonstrated in a U.S. Post Marketing Clinical Trial - World Health...

Leading Biotech Companies Kedrion Biopharma of Italy and Kamada Ltd. of Israel Continue Their Collaboration to Develop a New Anti-COVID Plasma-Based Treatment PR Newswire CASTELVECCHIO PASCOLI, Italy, Aug. 25, 2020 CASTELVECCHIO PASCOLI, Italy, Aug. 25, 2020 /PRNewswire/ -- Two innovative bio-pharma companies specialized in plasma-derived therapeutics - Kedrion Biopharma of Italy and Kamada Ltd. of Israel - are continuing their work on the development, manufacturing and clinical distribution of...

Les grandes sociétés de biotechnologie Kedrion Biopharma (Italie) et Kamada Ltd. (Israël) poursuivent leur collaboration pour développer un nouveau traitement anti-COVID à base de plasma PR Newswire CASTELVECCHIO PASCOLI, Italie, 25 août 2020 CASTELVECCHIO PASCOLI, Italie, 25 août 2020 /PRNewswire/ -- Deux sociétés biopharmaceutiques innovantes spécialisées dans les thérapies dérivées du plasma — l'italienne Kedrion Biopharma et l'Israélienne Kamada Ltd. — poursuivent leurs...

Führende Biotech-Firmen Kedrion Biopharma (Italien) und Kamada Ltd. (Israel) setzen ihre Zusammenarbeit zur Entwicklung einer neuen plasmabasierten Anti-COVID-Behandlung fort PR Newswire CASTELVECCHIO PASCOLI, Italien, 25. August 2020 CASTELVECCHIO PASCOLI, Italien, 25. August 2020 /PRNewswire/ -- Zwei innovative, auf plasmabasierte Therapeutika spezialisierte biopharmazeutische Unternehmen – Kedrion Biopharma aus Italien und Kamada Ltd. aus Israel – arbeiten weiter an der Entwicklung,...

Führende Biotech-Unternehmen Kedrion Biopharma (Italien) und Kamada Ltd. (Israel) kündigen globale Zusammenarbeit an, um neue plasmabasierte Anti-COVID-Behandlung zu beschleunigen PR Newswire CASTELVECCHIO PASCOLI, Italien, 29. April 2020 CASTELVECCHIO PASCOLI, Italien, 29. April 2020 /PRNewswire/ -- Zwei innovative Biopharma-Unternehmen, die sich auf aus Plasma gewonnene Therapeutika spezialisieren - Kedrion Biopharma aus Italien und Kamada Ltd. aus Israel - haben angekündigt, dass sie sich...

Les grandes sociétés de biotechnologie Kedrion Biopharma (Italie) et Kamada Ltd. (Israël) annoncent une collaboration mondiale pour accélérer le développement d'un nouveau traitement anti-COVID à base de plasma PR Newswire CASTELVECCHIO PASCOLI, Italie, 29 avril 2020 CASTELVECCHIO PASCOLI, Italie, 29 avril 2020 /PRNewswire/ -- Deux sociétés biopharmaceutiques innovantes spécialisées dans les produits thérapeutiques dérivés du plasma – Kedrion Biopharma (Italie) et Kamada Ltd....

Leading Biotech Companies Kedrion Biopharma of Italy and Kamada Ltd. of Israel Announce Global Collaboration to Speed New Anti-COVID Plasma-Based Treatment PR Newswire CASTELVECCHIO PASCOLI, Italy, April 29, 2020 CASTELVECCHIO PASCOLI, Italy , April 29, 2020 /PRNewswire/ -- Two innovative bio-pharma companies specialized in plasma-derived therapeutics - Kedrion Biopharma of Italy and Kamada Ltd. of Israel - have announced that they are joining forces for the development, manufacturing and...

NEW YORK, NY / ACCESSWIRE / May 16, 2017 / Kamada Ltd (NASDAQ: KMDA ) will be discussing their earnings results in their Q1 Earnings Call to be held May 16, 2017 at 8:30 AM Eastern Time. To listen to the event live – visit https://www.investornetwork.com/company/22013 . Replay Information The replay will be available online at https://www.investornetwork.com/company/22013 . About Investor Network Investor Network (IN) is a new financial content community, serving millions of unique investors...

VIDEO FINANCIAL REPORTING Why invest in is the first financial video platform where you can easily search through thousands of videos describing global ......

VIDEO FINANCIAL REPORTING Why invest in is the first financial video platform where you can easily search through thousands of videos describing global ......

NESS ZIONA, Israel, Feb. 01, 2017 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ:KMDA) (TASE:KMDA), a plasma-derived protein therapeutics company focused on orphan indications, announced today that it will release financial results for the fiscal year ended December 31, 2016 prior to the open of the U.S. financial markets on Monday, February 6, 2017. Kamada management will host an investment community conference call on Monday, February 6 at 8:30 a.m. Eastern time to discuss these results and answer...

NESS ZIONA, Israel, Jan. 23, 2017 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ:KMDA) (TASE:KMDA), a plasma-derived protein therapeutics company focused on orphan indications, announced today the positive Scientific Advice response from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) focused on the Company’s development program in Europe for Alpha-1 Antitrypsin (G1-AAT IV) for the treatment of acute Graft-Versus-Host Disease (aGvHD) with lower...

NESS ZIONA, Israel, Nov. 15, 2016 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ:KMDA) (TASE:KMDA) a plasma-derived protein therapeutics company focused on orphan indications, announced today that it has signed a collaboration agreement with Yissum Research Development Company of the Hebrew University of Jerusalem , for the development of an efficient and robust eukaryotic expression system for recombinant human Alpha 1 Antitrypsin (rhAAT). The goal of this development work is to maximize protein...

Total Revenues for Third Quarter 2016 Grew 21% to $19.4 Million vs. Third Quarter 2015 Proprietary Products Revenue Grew 57% to $15.0 Million in Third Quarter 2016 vs. Third Quarter 2015 Company Reiterates 2016 Revenue Guidance of $75 to $80 Million and 2017 Revenue Target of $100 Million Conference Call Today at 8:30 a.m. Eastern Time NESS ZIONA, Israel, Nov. 10, 2016 (GLOBE NEWSWIRE) -- Kamada Ltd. (Nasdaq:KMDA) (TASE:KMDA.TA), a plasma-derived protein therapeutics company focused on orphan...

PDUFA goal date of August 29, 2017 If approved, product would represent new treatment option in $100M-plus market where supply of post-exposure rabies treatment has been inconsistent over time FORT LEE, N.J. and NESS ZIONA, Israel, Nov. 07, 2016 (GLOBE NEWSWIRE) -- Kedrion Biopharma , and Kamada Ltd. (NASDAQ:KMDA) (TASE:KMDA), two leading human-derived protein therapeutics companies, today announced that the U.S. Food and Drug Administration (FDA) has accepted for review a Biologics License...

NESS ZIONA, Israel, Nov. 03, 2016 (GLOBE NEWSWIRE) -- Kamada Ltd. (Nasdaq:KMDA), a plasma-derived protein therapeutics company focused on orphan indications, announces that it will release financial results for the third quarter ended September 30, 2016 prior to the open of the U.S. financial markets on Thursday, November 10, 2016. Kamada management will host an investment community conference call on Thursday, November 10, 2016 at 8:30 a.m. Eastern time to discuss these results and answer...

NESS ZIONA, Israel, Nov. 02, 2016 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ:KMDA) (TASE:KMDA), a plasma-derived protein therapeutics company focused on orphan indications, today announced the clinical plan for the initiation of a Phase 2/3 clinical trial in the United States of its Alpha-1 Antitrypsin (G1-AAT IV) for the treatment of acute Graft-Versus-Host Disease (GvHD), in collaboration with Shire plc. Kamada and Shire (Baxter at the time) entered into an exclusive strategic cooperation...

NESS ZIONA, Israel, Oct. 06, 2016 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ:KMDA) (TASE:KMDA), a plasma-derived protein therapeutics company focused on orphan indications, announced today the extension of the strategic partnership with Shire plc (LSE:SHP) (NASDAQ:SHPG) for GLASSIA ® . Minimum revenue for GLASSIA in the extended agreement for the years 2017 to 2020 will reach approximately $237 million and may be expanded to $288 million during that period. Kamada will now continue to produce...